Nephrology
Renal Artery Stenosis
8
Pipeline Programs↗
1
Active Trials↗
7
Companies Involved↗
Renal artery stenosis is an early-stage landscape with 8 programs across 7 companies. The most active players are AstraZeneca, Lee's Pharmaceutical Limited, Bayer. 6 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 1
No programs
Phase 2
No programs
Phase 31
Analysis
Trial Status
8
clinical trials
Unknown status3 · 38%
Completed3 · 38%
Recruiting1 · 13%
Terminated1 · 13%
Clinical Trials
Trial Activity
8 trials
Compare Effects of Intensive Versus Conventional Lipid-lowering Therapy in Patients With Severe Atherosclerotic Renal Artery Stenosis Undergoing Stent Placement
Completed·—·Phase 2/3·NCT03521700·150 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)